Dawes, Kelsey
Andersen, Allan
Reimer, Rachel
Mills, James A.
Hoffman, Eric
Long, Jeffrey D.
Miller, Shelly
Philibert, Robert
Funding for this research was provided by:
National Institutes of Health
Article History
Received: 7 July 2021
Accepted: 18 October 2021
First Online: 3 November 2021
Competing interests
: Dr. Philibert is the Chief Executive Officer of Behavioral Diagnostics. The use of cg05575921 to assess smoking status is covered by existing and pending patents including US Patents 8,637,652 and 9,273,358. The use of DMR11 to impute cell heterogeneity is covered by pending patents assigned to Behavioral Diagnostics. Ms. Dawes, Mr. Mills, Drs. Andersen, Reimer, Hoffman and Long have no conflicts to report. Ms. Miller is an employee of Behavioral Diagnostics.